Sherry X. Yang, MD, PhD

Program Director

Dr. Sherry Yang joined the Cancer Diagnosis Program as a Program Director in 2019. She serves as a biomarker reviewer for the NCI CTEP-sponsored clinical trials and a member of the NCI ComboMATCH Molecular Biomarker and Specimen Management Committee; and developed the treatment-associated prognostic biomarker initiative at CDP. Dr. Yang was Chief of National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, NCI from 2006 to 2019. Her laboratory was engaged in the correlative science aspect of clinical trials, and developed and validated pharmacodynamic, response or toxicity biomarkers to targeted therapy and conventional therapy. She implemented translational research initiative for predictive and prognostic biomarkers in cancer treatment. Dr. Yang joined the NCI upon completion of fellowship training from the Johns Hopkins Oncology Center, Baltimore, Maryland in 2001. She has published over 80 research articles, reviews and book/book chapters, and is a recipient of several biomarkers-related awards and innovations. Focused on the biomarker-driven cancer treatment, she has been an editor of Handbook of Therapeutic Biomarkers in Cancer since 2010.